Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPC | P11150 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.33 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.33 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.33 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.33 |
| ▸ | PSMA1 | P25786 | 2/20 | 0.33 |
| ▸ | PSMA2 | P25787 | 2/20 | 0.33 |
| ▸ | PSMA3 | P25788 | 2/20 | 0.33 |
| ▸ | PSMA4 | P25789 | 2/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.33 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.33 |
| ▸ | PSMA5 | P28066 | 2/20 | 0.33 |
| ▸ | PSMB4 | P28070 | 2/20 | 0.33 |
| ▸ | PSMB6 | P28072 | 2/20 | 0.33 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.33 |
| ▸ | PSMB10 | P40306 | 2/20 | 0.33 |
| ▸ | PSMB3 | P49720 | 2/20 | 0.33 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.33 |
| ▸ | PSMA6 | P60900 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26189498 | 0.82 | CNR2 (0.35) | LIPCLIPGCETPPSMB11PSMA7 | |
| SCHEMBL26189285 | 0.81 | LIPC (0.35) | LIPCLIPGCETPPSMB11PSMA7 | |
| SCHEMBL22820229 | 0.80 | KDM1A (0.40) | LIPCLIPGPSMB11PSMA7PSMB1 | |
| SCHEMBL23877610 | 0.79 | KDM1A (0.41) | LIPCLIPGKDM1A | |
| SCHEMBL23877431 | 0.78 | CES2 (0.38) | LIPCLIPGPSMB11PSMA7PSMB1 | |
| SCHEMBL23877482 | 0.78 | KDM1A (0.51) | LIPCLIPGKDM1APLK1 | |
| SCHEMBL26188606 | 0.77 | PSMB11 (0.37) | LIPCLIPGCETPPSMB11PSMA7 | |
| SCHEMBL23877527 | 0.77 | KDM1A (0.39) | LIPCLIPGPSMB11PSMA7PSMB1 | |
| SCHEMBL23877461 | 0.77 | KIF11 (0.40) | LIPCLIPGPSMB11PSMA7PSMB1 | |
| SCHEMBL31046921 | 0.77 | DDR1 (0.38) | PSMB11PSMA7PSMB1PSMA1PSMA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20240409508-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | ORSOBIO, INC. | 2024-12-12 | — | — | US | disclosed |
| CN-118791407-A | Sulfinylamino group benzamide and process for preparing same Sulfonylamino benzamide derivatives | 奥索生物公司 | 2024-10-18 | — | — | CN | disclosed |
| CN-118638096-A | Sulfinylamino group benzamide and process for preparing same Sulfonylamino benzamide derivatives | 奥索生物公司 | 2024-09-13 | — | — | CN | disclosed |
| US-12049439-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| CN-112204008-B | Sulfonylaminobenzamides and sulfonylaminobenzamide derivatives | 奥索生物公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-3796975-B1 | SULFONYLAMINOBENZAMIDE DERIVATIVES | ORSOBIO INC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | GILEAD SCIENCES, INC. | 2022-02-24 | — | — | US | disclosed |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | THE LIVER COMPANY INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | THE LIVER COMPANY INC. (US) | 2021-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220055985-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | STS, SULT2A1, SCN2B | LIPC 2934/4885LIPG 3249/4885CETP 4143/4885 |
| US-12049439-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | STS, SULT2A1, SCN2B | LIPC 2934/4885LIPG 3249/4885CETP 4143/4885 |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | NR3C2, NR5A1, SRD5A2 | LIPC 1288/4885LIPG 3293/4885CETP 2083/4885 |
| US-20240409508-A1 | SULFINYLAMINOBENZAMIDE AND SULFONYLAMINOBENZAMIDE DERIVATIVES | STS, SULT2A1, SCN2B | LIPC 2934/4885LIPG 3249/4885CETP 4143/4885 |
| US-11136290-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | STS, SULT2A1, SCN2B | LIPC 2934/4885LIPG 3249/4885CETP 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.